Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years
The MASLD burden has increased globally and is projected to continue escalating. It is suggested that the MASLD screening be integrated into the non-communicable diseases program and be prioritized for monitoring in high-burden areas.
Authors
- Chenghao Su
- Ruixin Zhang (ORCID: https://orcid.org/0000-0002-2463-4839)
- Tingjuan He (ORCID: https://orcid.org/0000-0003-3481-3045)
- Wei Jiang (ORCID: https://orcid.org/0000-0003-0596-7811)
- Hongfei Mi
- Z X Lin (ORCID: https://orcid.org/0000-0003-1517-281X)
- Shuhao Ren
Institutions
- Xiamen University (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Ningbo No. 2 Hospital (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Ningbo No.6 Hospital (CN)
- Xiamen Tobacco Industry (China) (CN)
Publication Details
- Journal
- Preventive Medicine Reports
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.pmedr.2025.103248
- Citations
- 9
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.19